Shares Homepage - BSE Sensex, NSE Nifty, Latest Prices, Live News, Company Search, Result Annoucements, Company News, Top stories, Gainers Losers, Top Performers, Market Commentary, Live Quotes, Bulk Deals
India's preferred Personal finance destination
Home Shares News Centre F&O Mutual Funds IPO Portfolio Commodity Loans Financial Planning Insurance About Us
Markets Companies Research Industries E-Mail Page
Wealth Tracker    Newsletter   Tax Corner NRI Centre Forums E-Mail Chat Masala Feedback
my Last 5 Scrips
Company BSE Price(Rs) % Chg
Ong Corp 420.00 5.79
Hindalco 146.60 2.59
Axis Ban 417.55 3.88
Reliance 934.20 0.20
Tata Stl 449.60 0.41
Clear All Clear Last
Shares
NSE Live
Nifty Live Prices
Live Quotes
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
BSE Live
BSE30 Live Prices
Live Quotes
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Market Pulse
Leaders
Laggards
FII Activity
Mutual Fund Activity
Meetings
Results Watch
Results Calendar
Results Announced
IPO Watch
Company
Snapshots
Quotes
Charts
Financials
Recent News
Broker Research
Meetings
Research Tutorial
Discussion Forum
Research
Research Reports
Sector Watch
Economy Watch
Snapshot-Ind-Swift Laboratories Limited
Ind-Swift Laboratories Limited
Sector:Pharmaceuticals Pharmaceuticals - Bulk Drugs
BSE:532305NSE:INDSWFTLABBloomberg:ISL@INReuters:ISLB.BO
Market Lot: 1Face Value: 10ISIN Demat: INE915B01019
QuotesSnapshotChartsFinancialsResearchRecent News
Peer GroupAGM/AMMF HoldingDiscussion ForumBSE/NSE NoticesBSE/NSE Deals

 
 
Recent Developments
13-NOV-13 ICRA has upgraded the long term rating for Rs 9.48 billion of bank facilities of Ind Swift Laboratories to C from D. ICRA has also upgraded short term rating for Rs 2.99 billion of bank facilities of the company to A4 from D. The total rated limits are Rs 12.13 billion. 16-MAY-12 Ind-Swift added another feather in its cap by launching generic formulations of the World`s best selling drug Atorvastatin in UK in collaboration with Wock...   More..
Business Profile Future Plans
One To One
Recent news
Latest News
ICRA upgrades Ind Swift Laboratories to 'C'  -IRIS 13-Nov-13
Previous

More


Brief Financials (in Rs. Mn.) 
Period ending (months)30-Jun-2014(3)31-Mar-2014 (12)31-Mar-2013 (12)
Net sales 1841.099406.6210827.01
Other Income0.000.000.00
Total Income1841.099406.6210827.01
Cost of goods sold1594.319149.4110264.97
OPBDIT246.78257.21562.04
PAT-171.15-1227.44-1189.71
Gross Block---
Equity capital409.63409.63392.71
EPS (Rs.)--29.28-30.35
DPS (Rs.)---
BV (Rs.)---
P/E range (x)-NANA
Debt / Equity (x)---
Operating margin (% of OI)13.4 2.7 5.2
Net margin (% of OI)-9.3-13.0-11.0
Detailed Financials
Income 
Statement
Balance Sheet Latest 
Quarterly/Halfyearly
Ratio Analysis Share Statistics
Price Charts
Scrip Information



Registered Office
ADDRESS
SCO 850
Shivalik Enclave
NAC
Manimajra
Chandigarh
Union Territory-160 101
PHONE
(0172) 2730 503/ 2730 920
FAX
(0172) 2730 504/ 2736 294
 
Board of Directors
NSE/BSE Announcements


Home | Shares | F&O | Mutual Funds | Loans | Insurance | News Centre
Wealth Tracker | Tax Corner | NRI Centre | | Search in myiris | Advertise
All rights reserved. IRIS Business Services Limited
Disclaimer